Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 17/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064012 | 1.00 | CETP (0.43) | CETP | |
| SCHEMBL6063930 | 0.93 | CETP (0.42) | CETP | |
| SCHEMBL6435457 | 0.93 | CETP (0.42) | CETP | |
| SCHEMBL6277313 | 0.90 | CETP (0.43) | CETP | |
| SCHEMBL5669146 | 0.90 | CETP (0.43) | CETP | |
| SCHEMBL6566052 | 0.89 | IDO1 (0.43) | CETP | |
| SCHEMBL6568878 | 0.89 | IDO1 (0.43) | CETP | |
| SCHEMBL6435008 | 0.89 | CETP (0.40) | CETP | |
| SCHEMBL6570065 | 0.89 | CETP (0.42) | CETP | |
| SCHEMBL6064713 | 0.89 | CETP (0.40) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653926-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1581210-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578448-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1519754-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTASE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1519752-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005011634-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1474144-A1 | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR | Pfizer Products Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004004777-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004778-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTABLE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003063868-A1 | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |